News

News 16.10.2023 Zurich, Switzerland - 12.10.2023 Neurimmune announced today that preclinical data relating to its human antibody NI203 targeting pathologic aggregates of the beta cell peptide hormone islet amyloid polypeptide (IAPP) have been published in the current issue of Nature Communications. The paper “A human antibody against pathologic IAPP aggregates protects beta cells in...

Events, Internal events
Event date: 26.10.2023 When: Thursday, October 26, 5 PM Where: Bio-Technopark, Auditorium, Wagistrasse 25, 8952 Schlieren Research and development thrive on openness and free flow of information. However, research goals, strategies and, above all, results, are among the most valuable asset of a company. Collaboration therefore requires trust and clear rules on the use of...

News 14.10.2023 Schlieren (Zurich), Switzerland, October 12, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next-generation bone graft technologies, today provides an update on its commercial activities for the first nine months of 2023 and announces changes and a transition in responsibilities within the Executive Management. Direct sales of MagnetOs rose...

News 14.10.2023 Schlieren (Zurich), October 9, 2023 - LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform...

News 18.09.2023 Switzerland, 18 September 2023 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the launch of its Series C for the next stage of the company’s development. CUTISS seeks to raise the Series C with the participation of existing and new investors to...